Core Viewpoint - The company reported its 1H25 performance, showing revenue and net profit growth, driven by new production capacity and improved profit margins [1] Financial Performance - 1H25 revenue reached 2.995 billion yuan, a year-on-year increase of 6.21% - Net profit attributable to shareholders was 241 million yuan, corresponding to an earnings per share of 1.05 yuan, up 9.6% year-on-year - The increase in net profit was mainly due to the revenue increment from new lubricant additive capacity and profit margin improvement [1] - 1H25 non-GAAP net profit was 236 million yuan, reflecting an 11.6% year-on-year growth - In terms of product performance, revenue from antioxidant agents and lubricant additives grew by 3.06% and 18.49% to 2.36 billion yuan and 620 million yuan, respectively [1] - Gross margins for antioxidant agents and lubricant additives changed by -0.66 percentage points and +5.53 percentage points to 23.66% and 13.48%, respectively [1] - 2Q25 revenue was 1.51 billion yuan, with year-on-year and quarter-on-quarter growth of 3.3% and 2.2% - 2Q25 net profit attributable to shareholders was 133 million yuan, with year-on-year and quarter-on-quarter growth of 18.0% and 23.6% [1] - 2Q25 gross margin improved by 0.2 and 0.1 percentage points to 21.6% [1] Development Trends - The second phase of Jinzhou Kangtai's lubricant additive capacity is expected to enhance production efficiency, with 1H25 lubricant additive revenue at 618 million yuan, up 18.49% year-on-year [2] - The company is actively involved in the formulation of Chinese standards for engine lubricants and has made significant progress in collaborations with major international and domestic additive companies [2] - The establishment of the Life Sciences Division in 2021 aims to cultivate a new growth curve, focusing on bio-blocks and synthetic biology [2] - The company has made investments in high-end electronic-grade PI materials through the acquisition of Korean IPI, with production expected to start in 2026 [2] - An overseas R&D and production base is planned in Malaysia with an investment of up to 300 million USD, aimed at enhancing international competitiveness [2] Profit Forecast and Valuation - The company maintains its profit forecasts for 2025/26, with the current stock price corresponding to price-to-earnings ratios of 14.0x and 11.9x for 2025/26 [3] - Due to an upward adjustment in industry valuation, the target price has been raised by 20% to 38 yuan, indicating a 13% upside potential and corresponding P/E ratios of 15.8x and 13.4x for 2025/26 [3]

证券代码：300596 证券简称：利安隆 公告编号：2025-060 天津利安隆新材料股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 天津奥瑞芙生物医药有限公司（以下简称"奥瑞芙"）及天津奥利芙生物技 术有限公司（以下简称"奥利芙"）均为天津利安隆新材料股份有限公司（以下 简称"公司"或"利安隆"）的控股子公司。鉴于当前市场经济环境及行业发展 趋势，为优化资源配置，提高公司的管理效率和竞争力，经公司第五届董事会第 二次会议审议通过，同意以奥瑞芙为主体吸收合并奥利芙，奥瑞芙在吸收合并完 成后减少注册资本。 奥瑞芙为吸收合并方，奥利芙为被吸收合并方，本次交易完成后，奥利芙将 终止并注销法人资格，奥瑞芙将承继及承接奥利芙公司的全部资产、负债、业务、 人员、合同及其他一切权利与义务，奥瑞芙在吸收合并完成后减少注册资本。前 述交易完成后，公司对奥瑞芙的出资金额由 400 万元变为 650 万元，持股比例增 加至 50.71%，仍为奥瑞芙的控股股东。 天津聚康隆企业管理合伙企业（有限合伙）（以下简称"聚康隆"）是由公 司董事、高级管理人员及 ...

Summary of Key Points Core Viewpoint - Tianjin Lianlong New Materials Co., Ltd. has disclosed information regarding the pledge of shares by its controlling shareholder, Tianjin Lianlong Technology Group Co., Ltd., indicating a significant portion of shares are pledged as part of a repurchase transaction extension. Group 1: Shareholding and Pledge Details - The controlling shareholder, Tianjin Lianlong Technology Group, holds 32,461,290 shares, accounting for 14.14% of the company's total share capital. After the completion of the share pledge repurchase transaction extension, 16,086,200 shares are pledged, representing 49.56% of its holdings and 7.01% of the total share capital [1][2]. - Lianlong International Group, an action-in-concert party, holds 25,059,240 shares, which is 10.91% of the total share capital, with no shares pledged [1][2]. - As of the announcement date, the total number of pledged shares by the controlling shareholder and action-in-concert parties amounts to 16,086,200 shares, which is 7.01% of the company's total share capital [1][2]. Group 2: Pledge Extension and Impact - The announcement details the basic situation of the share pledge extension, with 4,840,000 shares pledged for financing, set to mature on August 26, 2025 [1][2]. - There is no risk of forced liquidation or transfer of pledged shares, and it is stated that this will not impact the company's operations or governance [2]. - The company will continue to monitor the situation regarding the pledged shares and fulfill its information disclosure obligations as required [2].

Core Insights - Lianlong (300596) reported a revenue of 2.995 billion yuan for the first half of 2025, representing a year-on-year growth of 6.21% [1] - The net profit attributable to shareholders reached 241 million yuan, up 9.60% year-on-year, with a basic earnings per share of 1.05 yuan, also reflecting a 9.61% increase [1] - The company has maintained a compound annual growth rate of 24.59% in revenue over the past fourteen years, demonstrating strong operational resilience despite international market challenges [1] Business Performance - The high polymer material anti-aging business generated 2.358 billion yuan in revenue, a 3.06% increase year-on-year, with a shipment volume of 65,500 tons, up 4.30% [2] - The lubricant additive business saw significant growth, achieving 618 million yuan in revenue, an 18.49% increase year-on-year, with a shipment volume of 34,200 tons, up 18.27% [2] - The life sciences business has transitioned to a market development phase, with key products achieving stable production and sales, and three products entering mass production [3] Strategic Developments - The company is expanding its global footprint, having established a wholly-owned subsidiary in Singapore and a subsidiary in Malaysia, with plans to invest up to 300 million USD in an overseas R&D and production base [3] - A new management team, primarily composed of individuals born in the 1980s, has taken over daily operations and innovation efforts, marking a significant generational transition for the company [4]

Core Viewpoint - Lianlong announced the approval of multiple proposals, including the 2025 semi-annual report and its summary, during the second meeting of the fifth board of directors [2] Group 1 - The company held its second meeting of the fifth board of directors on August 27 [2] - The meeting resulted in the approval of the proposal regarding the 2025 semi-annual report and its summary [2]

证券代码：300596 证券简称：利安隆 公告编号：2025-060 天津利安隆新材料股份有限公司 关于控股子公司间吸收合并及减资暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 1. 基本情况 天津奥瑞芙生物医药有限公司（以下简称"奥瑞芙"）及天津奥利芙生物技 术有限公司（以下简称"奥利芙"）均为天津利安隆新材料股份有限公司（以下 简称"公司"或"利安隆"）的控股子公司。鉴于当前市场经济环境及行业发展 趋势，为优化资源配置，提高公司的管理效率和竞争力，经公司第五届董事会第 二次会议审议通过，同意以奥瑞芙为主体吸收合并奥利芙，奥瑞芙在吸收合并完 成后减少注册资本。 奥瑞芙为吸收合并方，奥利芙为被吸收合并方，本次交易完成后，奥利芙将 终止并注销法人资格，奥瑞芙将承继及承接奥利芙公司的全部资产、负债、业务、 人员、合同及其他一切权利与义务，奥瑞芙在吸收合并完成后减少注册资本。前 述交易完成后，公司对奥瑞芙的出资金额由 400 万元变为 650 万元，持股比例增 加至 50.71%，仍为奥瑞芙的控股股东。 2. 构成关联关系的说明 ...

证券代码：300596 证券简称：利安隆 公告编号：2025-063 天津利安隆新材料股份有限公司 关于控股股东部分股份进行股票质押式回购交易展期的公告 控股股东天津利安隆科技集团有限公司保证向公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： ●天津利安隆新材料股份有限公司（以下简称"公司"）控股股东天津利安隆科 技集团有限公司（以下简称"利安隆集团"）持有本公司股份为 32,461,290 股，占 公司总股本的 14.14%，本次股票质押式回购交易展期业务办理完成后，已质押的股份 累计 16,086,200 股，占其持有公司股份总数的 49.56%，占公司总股本的 7.01%。 ●控股股东一致行动人利安隆国际集团有限公司（以下简称"利安隆国际"）持 有本公司股份为 25,059,240 股，占公司总股本的 10.91%，其中被质押的股份累计 0 股，占其持有公司股份总数的 0.00%，占公司总股本的 0.00%。 ●截至本公告日，控股股东、实际控制人及一致行动人合计持有 ...

天津利安隆新材料股份有限公司 2025 年半年度财务报告 天津利安隆新材料股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：天津利安隆新材料股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 1,571,061,722.48 | 1,067,577,159.35 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 64,077,448.30 | 162,727,144.86 | | 衍生金融资产 | | | | 应收票据 | 440,955,002.41 | 412,949,682.40 | | 应收账款 | 1,155,852,958.77 | 1,107,930,588.85 | | 应收款项融资 | 74,343,146.41 | 107,876,363.05 | | 预付款项 | 183,267,47 ...

2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：天津利安隆新材料股份有限公司 单位：人民币万元 法定代表人：范小鹏 主管会计工作的负责人：阎文嘉 会计机构负责人：阎文嘉 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 | 上市公司核算的会计 | 2025年期初占用资 | 2025年半年度占用累计 | 2025年半年度占用资金的 | 2025年半年度偿 | 2025年半年度期 | 占用形成原 因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 的关联关系 | 科目 | 金余额 | 发生金额（不含利息） | 利息（如有） | 还累计发生金额 | 末占用资金余额 | | | | 控股股东、实际控制人及其附 | - | - | - | - | - | - | - | - | - | - | | 属企业 | - | - | - | - | - | - | - | - | - | - | | 小计 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ...

天津利安隆新材料股份有限公司 董事会 2025 年 8 月 28 日 证券代码：300596 证券简称：利安隆 公告编号：2025-058 天津利安隆新材料股份有限公司 2025 年半年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 天津利安隆新材料股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开第五届董事会第二次会议，审议通过了《关于公司 2025 年半年度报告及 其摘要的议案》。为使投资者全面了解本公司的经营成果及财务状况，公司《2025 年半年度报告》及《2025 年半年度报告摘要》于 2025 年 8 月 28 日在中国证监 会指定的信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露，敬请投资者注 意查阅。 特此公告。 ...